The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...

Explore the intricate details of the Age-related Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Age-related Macular ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet ...